Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Berenberg & Goldman Sachs 9th German Corporate Conference 2020

49 slides from Fresenius SE & Co. KGaA's conference presentation, Sep 22, 2020

  1. Slide 1: Berenberg & Goldman Sachs 9th German Corporate Conference

    Berenberg & Goldman Sachs 9th German Corporate Conference 22-23 September 2020 Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: A Global Leader in Health Care Products and Services

    A Global Leader in Health Care Products and Services ~€35.4 bn in Sales Long-term opportunities (FY/2019) in growing, non-cyclical Leading market positions markets Global presence in 302,000+ employees Strong financial performance 100+ countries worldwide and cash flow generation (as of June 30, 202

  4. Slide 4: Global Sales Base in Growing, Non-Cyclical Markets

    Fresenius Group: Global Sales Base in Growing, Non-Cyclical Markets 2019 Sales by Region Sales in € bn 6% Africa 1 Latin America 4% 1% 1 CAGR 35,524 35,409 Asia-Pacific 33,886 33,530 11% €35.4 bn 29,471 27,995 Europe 43% North America 41% 4,688 4,599 4,830 4,599 1 4,561 4,001 4,302 2015 2016 2017 20

  5. Slide 5: Strong Track Record of Organic Sales Growth in All Business Segments

    Fresenius Group: Strong Track Record of Organic Sales Growth in All Business Segments Fresenius Group Business Segments 5% CAGR 8% 7% 7% 7% 7% 6% 6% 6% 6% 5% 5% 5% 4% 4% 4% ´15 ´16 ´17 ´18 ´19 ´15 ´16 ´17 ´18 ´19 ´15 ´16 ´17 ´18 ´19 16% 16% 6% 6% 5% 5% 4% 4% 3% 3% ´15 ´16 ´17 ´18 ´19 ´15 ´16 ´17 ´18

  6. Slide 6: Strong and Balanced Health Care Portfolio

    Strong and Balanced Health Care Portfolio Ownership: ~32% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services for Health Care Services Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc

  7. Slide 7: Fresenius Medical Care: Global Dialysis Market Leader

    Fresenius Medical Care: Global Dialysis Market Leader • The world’s leading provider of dialysis products Market Dynamics and services treating ~347,000 patients1 in ~4,000 clinics1 Global Dialysis Market 2019: • Provide highest standard of product quality and • ~€80 bn • ~6% patient growth p.a. pat

  8. Slide 8: Fresenius Kabi: A Leading Global Hospital Supplier

    Fresenius Kabi: A Leading Global Hospital Supplier • Comprehensive product portfolio for critically and Market Dynamics chronically ill patients • Strong Emerging Markets presence Global Addressable Market 2019: • Leading market positions • ~€97 bn Growth Drivers: • Patent expirations, rising demand

  9. Slide 9: Fresenius Helios: Europe's Largest Private Hospital Operator

    Fresenius Helios: Europe’s Largest Private Hospital Operator • Market leader in size and quality with excellent Market Dynamics growth prospects Hospital Market Size: • ~5%1 share in German acute care hospital • ~€102 bn2 German Acute Care Hospital Market ~12%1 share in Spanish private hospital mark

  10. Slide 10: Fresenius Vamed: Leading Global Hospital Projects and Services Specialist

    Fresenius Vamed: Leading Global Hospital Projects and Services Specialist • Manages hospital construction/expansion Market Dynamics projects and provides services for health care facilities worldwide Growth Drivers: • Offers project development, planning, turnkey • Emerging Market demand for buildin

  11. Slide 11: Global Trends offer Growth Opportunities for Fresenius

    Global Trends offer Growth Opportunities for Fresenius Aging Population Growing healthcare sector 6.3 % by 2050 Growth in emerging In 2019: 9% of the world 16 % markets + population is > age 651 over the next decade2 p.a. Increasing national income Chronically ill patients GDP per capita quadrupled

  12. Slide 12: Fresenius Group: Growth Areas

    Fresenius Group: Growth Areas Worldwide growing Growing Markets Marketing dialysis market with High Entry Attractive markets of existing Barriers value chain Standardizing Attractive Product Market Strengthening medical procedures Pipeline consolidation and extension of value chain Home dialysis Ent

  13. Slide 13: Medium-term Growth Targets 2020 – 2023 (CAGRs)

    Fresenius Group: Medium-term Growth Targets 2020 – 2023 (CAGRs) Organic sales growth 4 – 7% (plus ~1% small to mid-size acquisitions) confirmed Organic net income1 growth 5 – 9% (plus ~1% small to mid-size acquisitions) confirmed 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA B

  14. Slide 14: The Fresenius Strategy

    The Fresenius Strategy Improve profitability Drive Quality Internation- alization Hospital Dialysis supplies & products & Innovation services services Employees Better Hospital projects & medicine and Hospital operations services health care services for ever more people Forward thinking healthcare

  15. Slide 15: Our ESG Priorities: Patients, Employees and Compliance

    Our ESG Priorities: Patients, Employees and Compliance Serving the well-being Doing the right thing Being an attractive Protecting nature as Caring for of the patient employer the basis of life human rights  Quality of medical  Code of Conduct  Personnel structure  Water  No exploitative nor ou

  16. Slide 16: ESG Rating Overview

    ESG Rating Overview: Continuous Improvement through Reporting and Engagement Current Score CDP Climate: C 39/100 Prime C BBB 55/100 CDP Water: C DJSI Europe Sector Average CDP Climate: B- C- BBB - A 28 / 100 47 – 63/ 100 Previous Score CDP Climate: D- Prime C BB 33/100 48 /100 CDP Water: D- Next ste

  17. Slide 17: Sustainability/ESG: Decisive Steps for 2020

    Sustainability/ESG: Decisive Steps for 2020 Our Priorities • “Better medicine for more people” • Patients: Quality of products and services • People: Being an attractive employer • Compliance: Doing the right thing Sustainability Governance Remuneration • CEO sponsors Group sustainability efforts •

  18. Slide 18: Capital Deployment Focuses on Sustainable Value Creation

    Fresenius Group: Capital Deployment Focuses on Sustainable Value Creation Investments in own business Strategic acquisitions Dividends Share buy backs Leverage ratio 3.0-3.5 Berenberg & Goldman Sachs Conference 2020 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 18

  19. Slide 19: Proven Track Record of Deleveraging

    Fresenius Group: Proven Track Record of Deleveraging Net Debt/EBITDA1 Hospitals from 4 3.7x 4 3.6x 3.6x 4 3.5x 3,5 3.5 3.2x 3.2x 3.4x 4 3.1x 3 3.0x 3.0x 3.0x 3 2.8x 2.7x 2.7x 2.7x 2.6x 2.6x 2.6x 2.5x 2.7x 2,5 2.5 2.2x 2.3x 2.3x 2 2 2001 2002 2003 2004 2005 Q1/06 2006 2007 2008 2009 2010 2011 2012 20

  20. Slide 20: Fresenius SE: Earnings-Linked Dividend Policy

    Fresenius SE: Earnings-Linked Dividend Policy 2019 Pay-out Ratio: 24% Dividend Policy 0.84 0.80 • Dividend growth aligned to EPS 1 0.75 growth • Pay-out Ratio: 20% to 25% 0.62 0.55 Pay-out Ratio 0.44 0.42 € per share 0.37 0.32 Track record 0.29 Dividend 0.25 distribution 0.23 (€m) 25% 24% 24% 24% •

  21. Slide 21: Total Shareholder Return – CAGR, Rounded

    Total Shareholder Return – CAGR, Rounded 10 years 15 years 20 years 15% 14% 14% 13% 11% 10% 9% 8% 8% 8% 6% 3% DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 MSCI World Fresenius Fresenius Health Care Health Care Health Care Source: Bloomberg; divide

  22. Slide 22: Review Q2/20

    Review Q2/20 Berenberg & Goldman Sachs Conference 2020 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 22

  23. Slide 23: Q2/20: Successful crisis management amid the COVID-19 pandemic

    Fresenius Group Q2/20: Successful crisis management amid the COVID-19 pandemic Responsibility • Fresenius at the forefront to fight COVID-19 • Business continuity in plants, hospitals and sites ensured • Safety measures to protect patients and staff enhanced • Supplying COVID-19 patients with essent

  24. Slide 24: Fresenius Kabi: Gradual recovery in China, COVID-19 headwinds elsewhere

    Fresenius Kabi: Gradual recovery in China, COVID-19 headwinds elsewhere due to few elective treatments H1/20: Status quo Remainder of FY/20: Meaningful uncertainty China Postponement of elective procedures North COVID-related extra demand America Postponement of elective procedures COVID-related Eur

  25. Slide 25: Helios Germany: Occupancy rate deviation 2020 vs. 2019

    Helios Germany: Occupancy rate deviation 2020 vs. 2019 10% 0% Jan Feb Mar Apr May Jun -10% -20% -30% Occupancy rate 2020 vs. Occupancy rate 2019 Berenberg & Goldman Sachs Conference 2020 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 25

  26. Slide 26: Helios Germany: Gradual recovery of elective procedures in Q2

    Helios Germany: Gradual recovery of elective procedures in Q2 H1/20: Status quo Remainder of FY/20: Normalisation ahead Acute care Good organic Mandated postponement of elective procedures hospitals growth Lower capacities due to distance rules Patients’ willingness to seek elective procedures Incre

  27. Slide 27: Helios Spain: Q2 marked by significant COVID-19 headwinds

    Helios Spain: Q2 marked by significant COVID-19 headwinds, gradual recovery of elective treatments started only end of Q2 H1/20: Status quo Remainder of FY/20: Normalisation ahead Private Good organic Mandated postponement hospitals growth of elective procedures Patients’ willingness to seek electiv

  28. Slide 28: Fresenius Vamed: Ongoing headwinds due to COVID-19

    Fresenius Vamed: Ongoing headwinds in project and service business due to COVID-19 H1/20: Status quo Remainder of FY/20: Meaningful uncertainty Project Good organic growth Delays and cancellations of project orders business Execution delays due to travel/quarantine restrictions and supply chain rest

  29. Slide 29: During the COVID-19 pandemic, fulfilling our social responsibility

    Fresenius Group ”During the COVID-19 pandemic, Fresenius continues to make many important contributions to the provision of high-quality, affordable healthcare. We are standing with our patients around the world – fulfilling our social responsibility.“ Stephan Sturm Chairman of the Management Board

  30. Slide 30: Financial Review Q2/20

    Financial Review Q2/20 Berenberg & Goldman Sachs Conference 2020 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 30

  31. Slide 31: Q2/20 Profit and Loss Statement

    Fresenius Group: Q2/20 Profit and Loss Statement Sales EBIT +2% 0% Net Income Q2/20: €8,920 m Q2/20: €1,123 m -13% Income Tax Rate Net Interest Q2/20: €410 m 23.5% -€167 m Q2/19: 22.8% Q2/19: -€180 m All growth rates in constant currency (cc) Before special items Net income attributable to sharehold

  32. Slide 32: Q2/20 Business Segment Growth

    Fresenius Group: Q2/20 Business Segment Growth Organic sales growth EBIT growth (cc) +4% +25% +2% -5% -2% -29% -1% -159% +2% 0% All figures before special items For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-cen

  33. Slide 33: Fresenius Group: Cash Flow

    Fresenius Group: Cash Flow Operating CF Capex (net) Free Cash Flow1 €m Q2/2020 LTM Margin Q2/2020 LTM Margin Q2/2020 LTM Margin 2,319 25.2% -216 -6.2% 2,103 19.0% 437 18.3% -161 -10.7% 276 7.6% 295 9.2% -69 -5.0% 226 4.2% 28 1.8% -23 -3.8% 5 -2.0% Corporate/Other 3 n.a. -7 n.a. -4 n.a. 763 12.0% -26

  34. Slide 34: Fresenius Group: Strong financial position

    Fresenius Group: Strong financial position Well-diversified sales and Consistent Cash Generation earnings base Well-balanced maturity profile High financial flexibility Commitment ensured by broad mix of Solid IG Rating to long-standing financing instruments net debt/EBITDA target of 3.0-3.5x Excell

  35. Slide 35: FY/20 Financial Outlook by Business Segment

    Fresenius Group: FY/20 Financial Outlook by Business Segment (including COVID-19 effects) FY/19 H1/20 FY/203 €m (except otherwise stated) Base1 Actual FY/20e2 New Sales growth (org) 6,919 3,467 +3% to +6% +2% to +5% EBIT growth (cc) 1,205 581 -4% to +0% -6% to -3% Sales growth (org) 9,234 4,781 +3%

  36. Slide 36: FY/20 Financial Guidance

    Fresenius Group: FY/20 Financial Guidance (including COVID-19 effects) €m FY/19 H1/20 FY/20e2,3 (except otherwise stated) Base1 Actual2 FY/20e2 New Sales growth (cc) 35,409 +5% +4% to +7% +3% to +6% Net income4 1,879 -6% +1% to +5% -4% to +1% growth (cc) 1 Before special items, including IFRS 16 eff

  37. Slide 37: Attachments

    Attachments Berenberg & Goldman Sachs Conference 2020 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 37

  38. Slide 38: Kabi: Q2 & H1/20 Organic Sales Growth by Regions

    Fresenius Kabi: Q2 & H1/20 Organic Sales Growth by Regions Δ YoY Δ YoY €m Q2/20 organic H1/20 organic North America 600 3% 1,269 4% Europe 566 1% 1,197 5% Emerging Markets 512 2% 1,001 2% Total sales 1,678 2% 3,467 4% Berenberg & Goldman Sachs Conference 2020 © Fresenius SE & Co. KGaA Investor Relat

  39. Slide 39: Kabi: Q2 & H1/20 Organic Sales Growth by Product Segment

    Fresenius Kabi: Q2 & H1/20 Organic Sales Growth by Product Segment €m Q2/20 Δ YoY H1/20 Δ YoY organic organic IV Drugs 741 5% 1,537 6% Infusion Therapy 178 -9% 377 -5% Clinical Nutrition 456 1% 917 2% Medical Devices/ 303 2% 636 7% Transfusion Technology Total sales 1,678 2% 3,467 4% Berenberg & Gol

  40. Slide 40: Kabi: Q2 & H1/20 EBIT Growth

    Fresenius Kabi: Q2 & H1/20 EBIT Growth €m Q2/20 Δ YoY cc H1/20 Δ YoY cc North America 236 0% 493 1% Margin 39.3% -140 bps 38.8% -120 bps Europe 80 4% 184 13% Margin 14.1% +30 bps 15.4% +90 bps Emerging Markets 107 2% 178 -14% Margin 20.9% +20 bps 17.8% -280 bps Corporate and Corporate R&D -131 -18%

  41. Slide 41: Helios: Q2 & H1/20 Key Financials

    Fresenius Helios: Q2 & H1/20 Key Financials €m Q2/20 Δ YoY cc H1/20 Δ YoY cc Total sales 2,315 -2%1 4,781 1%1 Thereof Helios Germany 1,571 4%1 3,174 6%1 Thereof Helios Spain 743 -14%1 1,606 -7%1 Total EBIT 198 -29% 472 -14% Margin 8.6% -320 bps 9.9% -190 bps Thereof Helios Germany 147 -5% 312 3% Mar

  42. Slide 42: Helios: Key Metrics

    Fresenius Helios: Key Metrics H1/20 FY/19 Δ No. of hospitals Germany 86 86 0% - Acute care hospitals 83 83 0% No. of hospitals Spain 52 51 2% (Hospitals) No. of beds Germany 28,811 28,907 0% - Acute care hospitals 28,284 28,380 0% No. of beds Spain 7,832 7,288 7% (Hospitals) Admissions Germany (acut

  43. Slide 43: Vamed: Q2 & H1/20 Key Financials

    Fresenius Vamed: Q2 & H1/20 Key Financials €m Q2/20 Δ YoY cc H1/20 Δ YoY cc Total sales 475 1% 974 7% Thereof organic sales -1% 5% Project business 146 18% 288 24% Service business 329 -4% 686 1% Total EBIT -13 -159% 1 -97% Order intake1 50 -57% 174 -65% Order backlog1 2,745 -4%2 1 Project business

  44. Slide 44: Group: Q2/20 Key Financials

    Fresenius Group: Q2/20 Key Financials €m Q2/201 special Q2/20 Δ YoY cc1 items reported Sales 8,920 - 8,920 2% EBIT 1,123 - 1,123 0% Net interest -167 - -167 7% Income taxes -225 1 -224 -4% Net income2 410 1 411 -13% 1 Before special items 2 Net income attributable to shareholders of Fresenius SE & C

  45. Slide 45: Group: Calculation of Noncontrolling Interests

    Fresenius Group: Calculation of Noncontrolling Interests €m H1/20 H1/19 Earnings before tax and noncontrolling interests 1,907 1,887 Taxes -440 -435 Noncontrolling interests, thereof -592 -524 Fresenius Medical Care net income not attributable to Fresenius -431 -371 (H1/20: ~68%) Noncontrolling inte

  46. Slide 46: Group: Cash Flow

    Fresenius Group: Cash Flow €m Q2/20 LTM Margin Δ YoY Operating Cash Flow 3,082 18.6% 156% Capex (net) -476 -6.8% 14% Free Cash Flow 2,606 11.8% -- (before acquisitions and dividends) Acquisitions (net) -79 Dividends -153 Free Cash Flow 2,374 8.7% -- (after acquisitions and dividends) Berenberg & Gol

  47. Slide 47: Estimated COVID-19 effects Q2/H1 2020

    Estimated COVID-19 effects Q2/H1 2020 Growth cc Estimated as reported COVID-19 impact cc incl. COVID-19 €m Q2/201 H1/201 Q2/201 H1/201 Sales +2% +5% -4% to -5% -2% to -3% Net income2 -13% -6% -13% to -17% -9% to -13% 1 Before special items 2 Net income attributable to shareholders of Fresenius SE &

  48. Slide 48: Major Long Term Debt Maturities

    1,2 Fresenius Group: Major Long Term Debt Maturities All major remaining 2020 maturities already refinanced €m 4.000 4,000 Maturity 3.000 3,000 3.9 years2 on 2,021 average 2.000 2,000 1,926 2,071 238 584 1.000 1,000 698 1,740 1,657 500 1,016 1,100 947 650 750 750 77 500 500 357 0 68 2020 2021 2022 2

  49. Slide 49: Financial Calendar / Contact

    Financial Calendar / Contact Financial Calendar 29 October 2020 Results Q3/20 Please note that these dates could be subject to change. Contact Investor Relations & Sustainability Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: [email protected] For further information and current news: w

Fresenius SE & Co. KGaA — Berenberg & Goldman Sachs 9th German Corporate Conference 2020 on 6ix